O
LUMO

OrbiMed’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

OrbiMed’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-92,364
Closed -$8.46M – 146
2017
Q3 		$8.46M Sell
92,364
-112,747
-55% -$8.65M 0.08% 110
2017
Q2 		$13.6M Sell
205,111
-16,189
-7% -$2M 0.14% 92
2017
Q1 		$48M Hold
221,300
– – 0.54% 54
2016
Q4 		$20.5M Buy
221,300
+5,933
+3% +$669K 0.26% 68
2016
Q3 		$29.1M Buy
215,367
+39,644
+23% +$3.94M 0.33% 66
2016
Q2 		$17.8M Buy
175,723
+84,945
+94% +$10.5M 0.19% 76
2016
Q1 		$14.9M Sell
90,778
-15,367
-14% -$3.11M 0.16% 69
2015
Q4 		$34.8M Buy
106,145
+27,000
+34% +$8.79M 0.31% 59
2015
Q3 		$25.5M Buy
+79,145
New +$34.8M 0.26% 66
2015
Q2 		– Sell
-54,811
Closed -$27M – 152
2015
Q1 		$27M Buy
+54,811
New +$21.2M 0.23% 72

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's LUMO Position: Q4 2017 in Review

OrbiMed sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 92,364 shares — an estimated $8.46M sold.

OrbiMed first reported a position in LUMO in Q1 2015 and held it in 10 quarters. The position peaked at $48M in Q1 2017. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • OrbiMed reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • OrbiMed sold 92,364 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $8.46M.
  • OrbiMed first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2015 and held it in 10 quarters.
  • OrbiMed's Lumos Pharma, Inc. Common Stock position peaked at $48M in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.